Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
The practicalities of actually selling the controversial new Alzheimer’s drug are proving increasingly difficult for Biogen.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.